Loading…
Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
[...]GLP-1 RAs and SGLT-2 inhibitors are usually introduced at a similar T2D disease stage. [...]the fixed-effect estimates are relative levels of the outcome variable and estimated SD of random effects are interpretable as coefficients of variation.8 For the (log) distance between phlebotomies, a s...
Saved in:
Published in: | BMJ open diabetes research & care 2023-06, Vol.11 (3), p.e003300 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | [...]GLP-1 RAs and SGLT-2 inhibitors are usually introduced at a similar T2D disease stage. [...]the fixed-effect estimates are relative levels of the outcome variable and estimated SD of random effects are interpretable as coefficients of variation.8 For the (log) distance between phlebotomies, a simple random person effect was used, and only a single exposure variable for GLP-1 was used as fixed effect. In the ferritin dataset, 85% had a duration of HH of 0–15 years, whereas duration of drug exposure was mostly less than 5 years. [...]we showed relative ferritin levels across a HH duration of 0–15 years, using ferritin levels at 5 years of HH duration for a person not exposed to either drug class as reference. All data processing and analysis was done on anonymized data at Statistics Denmark’s server; SAS V.9.4 was used for data handling and R 4.1.0 with the Epi package was used for statistical analyses. |
---|---|
ISSN: | 2052-4897 2052-4897 |
DOI: | 10.1136/bmjdrc-2022-003300 |